Novavax, Janssen, and Astra-Zeneca conducted trials in South Africa that have dominant B.1.351 mutated strains. These studies demonstrated the lower vaccine efficacy compared to that of the other variants where this strain was not dominant . Vaccine efficacy for Brazilian variant (B.1.1.28) has not yet been reported.